Screener
PSCH vs PBE
Invesco S&P SmallCap Health Care ETF vs Invesco Biotechnology & Genome ETF
Key differences
- PSCH costs 0.29% less per year.
- Over the last 3 years, PBE has delivered higher annualized returns.
- PBE has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| PSCH | PBE | |
|---|---|---|
| Annual cost (TER) | 0.29% | 0.58% |
| Fund size (AUM) | $129M | $247M |
| Since | 2010 | 2005 |
| Dividend yield | 0.01% | 1.09% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +12.3% | +35.8% |
| CAGR 3Y | +1.0% | +10.3% |
| CAGR 5Y | -5.7% | +3.5% |
| Sharpe 3Y | -0.01 | 0.41 |
| Volatility 1Y | 20.29% | 18.63% |
| Max drawdown | -47.32% | -37.84% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to PSCH and PBE
Explore further